Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OraQuick Advance test marketing

This article was originally published in The Tan Sheet

Executive Summary

A consumer counseling system with 24-hour phone and online assistance will be developed for use with the OraQuick Advance Rapid HIV-1/2 Antibody Test in the OTC market, according to an agreement OraQuick marketer OraSure and health services provider Constella Group announce April 12. In addition to helping customers use OraQuick, the system will provide medical referrals when needed, according to a release. It also will be a "critical component" of product development as OraSure prepares to apply to FDA for OTC approval of OraQuick, the company said. OraSure, which expects to continue conducting clinical work on the product into 2008, received support for nonprescription marketing of the product from an FDA advisory committee in 2005 (1"The Tan Sheet" Nov. 7, 2005, p. 7)...

You may also be interested in...



Advisory Panel Shows Support for OTC HIV Test, Highlights Community Need

Over-the-counter availability of a rapid HIV test would provide a public health benefit, members of FDA's Blood Products Advisory Committee generally agreed at a Nov. 3 meeting in Gaithersburg, Md

Epizyme’s Tazverik Gets To Market In Rare Sarcoma, Paving Way To Bigger Indications

Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.

Shuttered US Supplement Firm Meets Recall Deadline, But Schumer Says FDA Late Cleaning Up Industry

While contract manufacturer ABH Nature' complied with consent decree, Sen. Chuck Schumer says FDA is late in enforcing against noncompliant firms across the supplement sector. Other recent consumer health recalls include more OTC ranitidine tablets due to the potential carcinogen NDMA found in the heartburn ingredient and four versions of Sure 48HR Anti-Perspirant & Deodorant with labeling errors.

Topics

UsernamePublicRestriction

Register

PS100410

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel